Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Capricor Therapeutics (CAPR) Stock Up +3.61% Today?

Why Is Capricor Therapeutics (CAPR) Stock Up +3.61% Today?

Key Takeaways

  • Capricor Therapeutics (CAPR) rose 3.61% to $8.32 in midday Thursday trading, a gain of $0.29 from the prior close of $8.03.
  • No new company release, SEC filing, or analyst rating change was published on Thursday, leaving the move without a company-specific catalyst.
  • The dominant driver is positioning ahead of a binary regulatory event: the FDA's Nov. 22 target action date for deramiocel in Duchenne muscular dystrophy.
  • The stock is also retracing part of Wednesday's 4.52% decline, a session in which it traded as high as $9.49 before closing near the bottom of its range.
  • Biotech was firm but not euphoric — XBI up about 0.6% and IBB up 0.3% — while small caps slipped, with IWM down roughly 1.2%.
  • News Significance Score: 13/100 — no fresh verified news and a price move well inside this stock's ordinary daily range.
  • Traders are now watching the label's scope for patients older than nine and whether the agency acts before or after the weekend.
  • Detailed Price Targets, Earnings, and Forecast data are available on dedicated pages for readers who want the full fundamental picture.
  • For rules-based exposure to volatile names like this, explore Trending AI Robots.

Opening Summary

Capricor Therapeutics (CAPR) is a San Diego-based clinical-stage biotechnology company developing cell and exosome therapies for rare diseases, led by deramiocel, an investigational allogeneic cell therapy for Duchenne muscular dystrophy. Shares changed hands at $8.32 on Thursday, up $0.29, or 3.61%, from the previous session's close of $8.03. The direction is unambiguously higher, but the driver is not a fresh disclosure. No company news, filing, or analyst action appeared before the move; the advance reflects pre-decision positioning into an FDA action date now three days away, layered on a rebound from Wednesday's late-session selloff.

No Company-Specific Catalyst Found in Thursday's Tape

No verified news or fundamental catalyst found in Thursday's flow. The absence is itself informative: with the regulatory calendar fixed, there was nothing new to price other than the passing of time toward Nov. 22. The internals fit a familiar pre-event pattern rather than a new disclosure — a gap higher to $9.12 shortly after the open, a fade back to roughly $8.02 within two hours, and a renewed push into the afternoon, all inside a day range of about 18%. That whipsaw behavior is consistent with speculative two-way hedging around a binary outcome, not with an information shock.

Positioning Ahead of the Nov. 22 FDA Decision

The substance driving sentiment was already public. The FDA reset the Prescription Drug User Fee Act target date for deramiocel to Nov. 22, 2026 after Capricor filed a major amendment built on 24-month HOPE-3 open-label extension data and more than 900 robustness re-analyses, alongside a narrowed proposed indication covering upper-limb function in patients older than nine. HOPE-3 met its primary endpoint with a 1.1-point advantage on the PUL 2.0 measure (p=0.029). Against that sits a July advisory committee vote of 9-3 against the cardiomyopathy evidence — a vote that did not address the upper-limb endpoint, but which has kept approval expectations firmly two-sided.

Because the payoff is binary, small shifts in perceived odds translate into outsized percentage moves. Wednesday illustrated the mechanism: the stock rallied early on news that the White House had withdrawn its nominee to lead the FDA, then surrendered the entire gain and closed down 4.52% on 8.4 million shares. Thursday's bounce partially reverses that markdown rather than establishing a new trend.

Market Context and Trading Activity

Roughly 1.9 million shares had traded by late morning, putting the session on pace to meet or exceed the stock's average volume of about 4 million shares — active, but short of the conviction seen Wednesday. Sector signals were mixed: large-cap biotech edged higher, while the small-cap Russell 2000 proxy fell, meaning Capricor's gain was idiosyncratic rather than a tide-lifting move. Technically, the shares remain far below their 50- and 200-day averages and about 79% under the 52-week high of $40.37, with $7.71 intraday and $7.99 from Wednesday acting as near-term support, and $9.12-$9.49 the immediate ceiling. Market capitalization sits near $500 million.

News Significance Score

The scale runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This session earns a 13 out of 100. The verified news component is weak: nothing new was disclosed Thursday, and the only live catalyst is a scheduled regulatory date that has been public since August. The price component is equally muted — at 3.61%, the move was only about 0.65 times the stock's typical absolute daily change of roughly 5.6% over the past 60 sessions. Larger single-session swings occurred 38 times in that window. With neither component strong, the score stays low.

What Comes Next for CAPR

The decisive variable is the FDA's action on the deramiocel BLA, targeted for Nov. 22, with the label's wording — particularly the age cutoff and functional endpoint language — mattering as much as the approval itself. A Rare Pediatric Disease designation could also yield a priority review voucher. Beyond the decision, investors face the distribution dispute with NS Pharma, which heads to arbitration in mid-2027, and a balance sheet carrying $198.5 million in cash after a $42.7 million third-quarter loss and a roughly 10% workforce reduction. Final Phase 1 StealthX vaccine data are expected in the first half of 2027, and the next scheduled financial report is due around March. The principal risk is a complete response letter, which would leave a pre-revenue company burning roughly $45 million a quarter.

Trending AI Robots

Tickeron operates hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions evolve. For readers navigating event-driven volatility like Capricor's, it offers a structured way to see which automated approaches are currently working. Review the page to compare live performance before deciding what fits your process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CAPR

Contributor

Dem Sem's AvatarDem Sem|Expert

CAPR in upward trend: 10-day moving average crossed above 50-day moving average on November 11, 2026

The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on October 29, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.

Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for CAPR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In 71 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

CAPR moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.592). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (442.120).

The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Develops innovative products for the treatment of cardiovascular diseases

Industry Biotechnology

Industry
Biotechnology
Address
10865 Road to the Cure
Phone
+1 858 727-1755
Employees
160
Web
https://www.capricor.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.